Skip to Main Content

24-1136 2025 Prior Authorization Changes to Medical Benefit Medication

Date: 10/22/24

Learn which drugs have been added, changed or removed from prior authorization requirements

The following update includes prior authorization (PA) changes for Medi-Cal fee-for-service physicians and other providers servicing Community Health Plan of Imperial Valley members. These changes all apply to outpatient pharmaceuticals (submitted under the medical benefit).

Additions, effective January 1, 2025

The following require PA.

Requirement

Code and description

Comments

Anktiva®

J9999, Not otherwise classified, antineoplastic drugs

N/A

BeqvezTM

J3590 Unclassified biologics

N/A

BkemvTM

J1300, Injection, eculizumab, 10 mg

Code currently requires authorization: Soliris®

ImdelltraTM

J3590, Unclassified biologics

N/A

Imlygic®

J9325, Injection, talimogene laherparepvec, per 1 million plaque forming units

Gene therapy

Ketalar®

J3490, Unclassified drugs

N/A

LenmeldyTM

J3590, Unclassified biologics

N/A

Leukine®

J2820, Injection, sargramostim (GM-CSF), 50 mcg

N/A

Tevimbra®

J3490, Unclassified drugs

PD 1 inhibitor

Tyenne®

J3262, Injection, tocilizumab,
1 mg

Code currently requires authorization: Actemra®

 

Changes, effective January 1, 2025

The following are changes to existing PA requirements.

Requirement

Code and description

Comments

Darzalex®

  • J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
  • J9145 Injection, daratumumab, 10 mg

Changed to Darzalex/Darzalex Faspro®

NyvepriaTM

Q5122 Injection, pegfilgrastim-apgf, biosimilar, 0.5 mg)

Changed to preferred

Ziextenzo®

Q5120 Injection, pegfilgrastim-bmez, biosimilar, 0.5 mg)

Changed to nonpreferred

 

Deletions, effective January 1, 2025

The following no longer require PA.

Requirement

Code and description

BCG Intravesical

J9030 BCG live intravesical instillation, 1 mg

Nuzyra®

J0121 Injection, omadacycline, 1 mg

Sandostatin®

J2354 Injection, octreotide, nondepot form for subcutaneous or intravenous
injection, 25 mcg

SensiparTM

J0604 Cinacalcet, oral, 1 mg, (for end-stage renal disease on dialysis)

 

Additional information

If you have questions regarding the information contained in this update, contact Community Health Plan of Imperial Valley at 833-236-4141. Behavioral Health providers can call 844-966-0298.
 

This information applies to Physicians, Participating Physician Groups (PPGs), Hospitals, Ancillary Providers, and Behavioral Health Providers.

This information applies to Medi-Cal in Imperial county.



Last Updated: 10/17/2024